Close Menu

NEW YORK – Mission Bio announced on Thursday that it has received a $2 million Small Business Innovation Research grant from the National Cancer Institute to develop a targeted sequencing panel to quantify minimal residual disease in acute myeloid leukemia.

The two-year grant, which was awarded Sept. 12 and is worth $1 million each year, will fund a partnership with researcher Jerald Radich of the Fred Hutchinson Cancer Research Center.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
14

This webinar will describe a rapid metagenomics assay under development for human pathogens, including the SARS-CoV-2 coronavirus.

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

Jul
23

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.